Fig. 4.

FZD2 induces EMT at TGF-β1 related manner. a EMT markers (E-cadherin, N-cadherin, Vimentin and Fibronectin) were examined by western blot in indicated BC cells. b EMT markers were detected by qRT-PCR at mRNA levels. c The intensity of E-cadherin and Vimentin was tested by immunofluorescence. d Expression correlation of TGF-β1 with FZD2 in BC patient samples was analyzed based on GEPIA database. e The mRNA and protein level of TGF-β1 was measured in BC cells transfected with si-NC or FZD2-specific siRNAs. f EMT markers (E-cadherin, N-cadherin, Vimentin and Fibronectin) were tested in BC cells treated with TGF-β1 (0, 2, 5 and 10 ng/ml) for 24 h. g qRT-PCR was used to analyze the mRNA levels of EMT markers in TGF-β1-strengthened BC cells. h The levels of related proteins (E-cadherin, N-cadherin, Vimentin, Fibronectin) were measured by western blot in BC cells pre-treated with SB431542 (5 μM) for 2 h, followed by TGF-β1 (10 ng/ml) incubation for another 24 h. i The levels of related proteins (E-cadherin, N-cadherin, Vimentin, Fibronectin) were measured by western blot in BC cells pre-treated with TGF-β1 (10 ng/ml) or SB431542 (10 ng/ml) for 24 h, followed by siFZD2 or oxFZD2 incubation for another 48 h. ^*p < 0.05, ^**p < 0.01, ^***p < 0.001 was a symbol of statistical significance. FZD2, frizzled class receptor 2; BC, breast cancer; EMT, epithelial-to mesenchymal transition